Amylyx Pharmaceuticals Overview
Valuation check: AMLX's ROE is -63.59%, below the sector sector average of -5.68%.
Get informed when a big investor buys or sells
+ Follow-63.59%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for AMLX is -63.59%. That is below the sector sector average of -5.68%. Investors often review this figure alongside Amylyx Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, AMLX currently prints -63.59% for ROE, while the sector average sits near -5.68%. That is roughly 1019.1% below the sector mean. Large gaps often invite a closer look at Amylyx Pharmaceuticals's growth, margins, and balance sheet.
Return on Equity shows how effectively Amylyx Pharmaceuticals converts resources into returns. At -63.59%, AMLX may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting AMLX's ROE (-63.59%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
